For example, Ipilimunab, an IgG1 antibody-based melanoma treatment, is a T cell potentiator that blocks CTLA-4 to stimulate T cell proliferation and stem malignant disease progression by delaying tumor progression and has been shown to significantly increase life expectancy [19,67,68]. This evidence concerns the gene CTLA4 and neoplasm.